:  +1-617-803-9415
search
Our Service
Syngeneic Mouse Model

PharmaLegacy provides a panel of extensively-validated syngeneic mouse models for preclinical immunotherapy research, used to interrogate novel immune-oncology treatments. We have model types including subcutaneous, orthotopic and metastatic. Our suite of syngeneic mouse models includes 22 models covering 14 cancer types, which have been validated with anti-PD-1, PD-L1 and anti-CTLA-4 antibodies. Additional models are in development.


Mouse PD1 and CTLA4 Ab Test in CT26 Model

Animal:  Female BALB/c mice (from SLAC), 7~8 weeks.

Tumor Cell:  CT26.WT, subcutaneous implantation.

Reagent:  Anti-m-CTLA-4, Anti-m-PD-1


Dosing started on Day10 post inoculation.

Animal:  Female BALB/c mice (from SLAC), 4~5 weeks.

Tumor Cell:  CT26.WT, subcutaneous implantation.

Reagent:  Anti-m-PD-1 5mg/kg QW*3 i.p.

                Anti-m-PD-1 1mg/kg QW*3 i.p.

10-2.png


Animal:  Female C57BL/6 mice (from SLAC), 5~6 weeks.

Tumor Cell:  H22, subcutaneous implantation.

Reagent:Anti-m-PD-1 5mg/kg QW*3 i.p.

10-3.png


PD-L1PD1/ Ab Dose-Finding for Combination(mc-38)

10-4.png

Animal:  Female C57BL/6 mice (from SLAC), 5~6 weeks.

Tumor Cell:  MC-38, subcutaneous implantation.

Reagent1:  Anti-m-PD-1 5mg/kg QW*3 i.p.

                  Anti-m-PD-1 1mg/kg QW*3 i.p.

Reagent2:  Anti-m-PD-L1 5mg/kg BIW*3 i.p.

                  Anti-m-PD-L1 5mg/kg QW*3 i.p.


Immunocyte-Profiling in Tumor in MC-38 Model

10-5.png

G4:  PD-L1 Ab

10-6.png




Fill out my online form